���景与受体作用机制 — Deep Dive

By Editorial Desk · published 2026-03-20 · last reviewed 2026-04-05 · Data

Everything below concerns 胃饥饿素受体. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Last reviewed on 2026-04-05. Where a claim depends on a specific study, the study is described rather than over-claimed.

背景与受体作用机制

现有文献多来自小规模、短期的研究，涉及生长激素缺乏、术后肠麻痹等方向。长期使用是否导致受体脱敏，以及重复给药后效应是否衰减，仍属开放问题。不同研究之间的剂量、给药途径和受试者特征差异较大，因此结论外推需谨慎。关于临床获益的确切证据尚不充分，需要更大规模的对照试验来澄清。

Ipamorelin 是一种合成五肽，在 20 世纪 90 年代被报道为生长激素促分泌剂。其结构基于胃饥饿素受体激动剂的设计思路，但并非天然激素。早期药理学研究显示，它可刺激垂体释放生长激素，而对应激激素轴的影响相对较小。该化合物常被用作研究生长激素调节通路的工具分子。

Background And Receptor Mechanism

At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor, also called the ghrelin receptor or GHS-R1a. Binding to this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to growth hormone release. The effect is mediated through phospholipase C and calcium mobilization rather than through the cyclic AMP pathway used by growth hormone releasing hormone. The two pathways are complementary, and combined stimulation produces a larger response than either alone.

Compared with other secretagogues such as GHRP-2, GHRP-6, and hexarelin, ipamorelin is described as more selective. Published animal work reports little or no increase in adrenocorticotropic hormone, cortisol, or prolactin at doses that release growth hormone. This selectivity is the property most often cited in the research literature. Whether the same profile holds across species and dosing schedules remains an open question, since human data are limited and come largely from small studies.

Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, and its molecular mass is approximately 711.9 daltons. The compound was described in the late 1990s by researchers seeking molecules that release growth hormone with fewer side effects than earlier secretagogues. It is a laboratory and research compound, not an approved medicine in most jurisdictions.

Ipamorelin at a glance

Background and Structural Identity

Ipamorelin is a synthetic pentapeptide classified as a growth hormone secretagogue. Its sequence, Aib-His-D-2-Nal-D-Phe-Lys-NH2, combines three non-proteinogenic residues with a C-terminal amide. The N-terminal aminoisobutyric acid unit and the two aromatic D-amino acids distinguish it from peptides assembled only from standard L-amino acids. Its formula is C38H49N9O5, corresponding to an average mass near 711.9 Da. At neutral pH the molecule carries a net positive charge, a property that shapes its behaviour in chromatographic and electrophoretic systems.

The compound was developed at Novo Nordisk during the 1990s as part of a programme seeking secretagogues with improved selectivity. It was described in the peer-reviewed literature in 1998 alongside related pentapeptides from the same series. Investigators advanced it because it raised growth hormone output in animal models while leaving other pituitary hormones comparatively unaffected. The development code NNC 26-0161 appears in earlier reports, and ipamorelin later became the common designation in published work.

Related pages on this site

• Connected reference
• Robust toolkit
• Optimized checklist
• Standard summary
• Balanced briefing
• Clear analysis
• Tracked review
• Quality dataset

Analytical Characterisation and Storage

Mass spectrometry confirms identity and reveals structural deviations that chromatography alone can miss. Positive-mode electrospray ionisation generally yields multiply charged ions whose deconvoluted mass is checked against the theoretical value. Amino acid analysis, and enzymatic digestion with subsequent fragment mapping, provide independent confirmation of sequence and of the terminal amide. Analysts take care to separate the target from deletion sequences, which may differ by one residue and therefore by only a small mass increment.

The lyophilised solid is normally held at -20 °C or colder, shielded from light and moisture. Stability in that state is measured in years, although shelf life depends on residual water content and the container seal. Once dissolved, the peptide is more fragile: aqueous solutions are commonly kept at 2-8 °C and used within days to weeks, and repeated freeze-thaw cycling is avoided. Strongly acidic or basic conditions accelerate hydrolysis, and prolonged exposure to them can strip the terminal amide.

Purity assessment for this peptide relies mainly on reversed-phase high-performance liquid chromatography. A C18 column with a water-acetonitrile gradient containing trifluoroacetic acid separates the target from truncated sequences and oxidation products. Detection near 214 nm exploits the amide backbone, while the aromatic side chains allow additional monitoring close to 280 nm. Reported purity values depend on the method, so a certificate of analysis carries weight only when gradient, column and integration parameters are given.

Receptor Mechanism and Secretagogue Action

Ipamorelin is a synthetic pentapeptide that acts on the growth hormone secretagogue receptor, also known as the ghrelin receptor. Its sequence contains five amino acid residues, including a non-natural residue that increases stability against enzymatic breakdown. The compound was developed in the 1990s as part of research into small peptides that stimulate pituitary hormone release. Unlike larger protein hormones, it can be produced by solid-phase peptide synthesis and characterized by standard analytical methods.

At the receptor level, ipamorelin binds GHS-R1a and triggers signaling through Gq-coupled pathways. Activation leads to calcium release and downstream effects in pituitary somatotroph cells. These events promote the release of growth hormone into circulation. The response depends on the presence of the receptor and on the physiological state of the animal or tissue studied. Because the receptor is also found in other tissues, effects beyond the pituitary have been examined in laboratory models, though the extent of those effects remains an area of ongoing study.

One distinguishing feature reported in animal studies is selectivity. Ipamorelin stimulated growth hormone release with limited elevation of adrenocorticotropic hormone or cortisol compared with earlier secretagogues such as GHRP-6. This pattern has been described as more selective for the growth hormone axis. The finding comes mainly from preclinical work, and the degree to which it holds across species and doses is not fully settled. Reports also describe effects on gastric motility in animal models, suggesting activity outside the pituitary, though the clinical relevance of this observation is uncertain.

Reference notes

=== Tertiary dentin (including reparative dentin and reactionary dentin) – pathologic === Tertiary dentin is dentin formed as a reaction to external stimulation such as cavities and wear. It is of two types, either reactionary, where dentin is formed from a pre-existing odontoblast, or reparative, where newly differentiated odontoblast-like cells are formed due to the death of the original odontoblasts, from a pulpal progenitor cell. Tertiary dentin is only formed by an odontoblast directly affected by a stimulus; therefore, the architecture and structure depend on the intensity and duration of the stimulus, e.g., if the stimulus is a carious lesion, there is extensive destruction of dentin and damage to the pulp, due to the differentiation of bacterial metabolites and toxins. Thus, tertiary dentin is deposited rapidly, with a sparse and irregular tubular pattern and some cellular inclusions; in this case, it is referred to as "osteodentin". Osteodentin is seen in Vit.A deficiency during development. However, if the stimulus is less active, it is laid down less rapidly with a more regular tubular pattern and hardly any cellular inclusions. The speed at which tertiary dentin forms also varies substantially among primate species.

=== Medical use === The appeal of conotoxins for creating pharmaceutical drugs is the precision and speed with which the chemicals act; many of the compounds target only a particular class of receptor. This means that they can reliably and quickly produce a particular effect on the body's systems without side effects; for example, almost instantly reducing heart rate or turning off the signaling of a single class of nerve, such as pain receptors. Ziconotide, a powerful atypical painkiller, was initially isolated from the venom of the magician cone snail, Conus magus. It was approved by the U.S. Food and Drug Administration in December 2004 under the name Prialt. Other drugs based on cone snail venom targeting Alzheimer's disease, Parkinson's disease, depression, and epilepsy are in clinical or preclinical trials. Many peptides produced by the cone snails show prospects for being potent pharmaceuticals, such as AVC1, isolated from the Australian species, the Queen Victoria cone, Conus victoriae, and have been highly effective in treating postsurgical and neuropathic pain, even accelerating recovery from nerve injury. Geography and tulip cone snails, as well as the Conus kinoshitai, are known to secrete a type of insulin that paralyzes nearby fish by causing hypoglycaemic shock. They are the only two non-human animal species known to use insulin as a weapon. Cone snail insulin is capable of binding to human insulin receptors and researchers are studying its use as a potent fast-acting therapeutic insulin.

=== Psoriatic arthritis === In psoriatic arthritis (PsA), inhibitors of TNF, such as infliximab, improve the signs and symptoms. Several therapies with modest efficacy have been studied in nail psoriasis. Among available agents, higher quality data are available to support the efficacy of cyclosporine and infliximab. Based on studies in AS, the results suggest infliximab, etanercept, and adalimumab have the potential to reduce the signs and symptoms of moderate to severely active axial involvement in PsA in patients who have had an inadequate response to NSAID (level 1a, grade A). The anti-TNF agents (infliximab and etanercept; level 1b, grade A) are more effective for the treatment of enthesitis than traditional agents. Results suggest infliximab is effective for the treatment of dactylitis in PsA.

Another case was that of Ismil bin Kadar, who was initially sentenced to death for a 2005 robbery-murder case in Boon Lay, but eventually acquitted of the crime as the Court of Appeal found that based on the evidence, Ismil was not involved in the case and that it was solely his younger brother Muhammad bin Kadar who was responsible for the robbery and murder; Muhammad was subsequently executed in April 2015. Successful clemency applications are thought to be even rarer. Since 1965, the presidential clemency has been granted seven times to death row inmates, whose sentences were all commuted to life imprisonment (not counting the clemency pleas of the underaged offenders serving TPP). The most recent case was in August 2025, when convicted drug trafficker Tristan Tan Yi Rui was granted clemency by President Tharman Shanmugaratnam, who commuted Tan's death sentence to life imprisonment. Prior to Tan's pardon, the last presidential clemency to be granted was in April 1998, when President Ong Teng Cheong pardoned a 19-year-old death row inmate and convicted murderer Mathavakannan Kalimuthu, commuting his death sentence to life imprisonment. Previously, other than the Court of Appeal, offenders were allowed to file criminal or civil appeals to the Privy Council in London, where the judges could hear their appeals once they exhausted all avenues of appeal in Singapore. This avenue of appeal was fully abolished for all criminal and civil matters in April 1994. One case in which an appeal to the Privy Council was successful was the case of murderer Mohamed Yasin bin Hussin.

Sources: en.wikipedia.org

Notes from published material

Nicotinic acid adenine dinucleotide phosphate (NAADP) is a Ca2+-mobilizing second messenger synthesised in response to extracellular stimuli. Like its mechanistic cousins, IP3 and cyclic adenosine diphosphoribose (Cyclic ADP-ribose), NAADP binds to and opens Ca2+ channels on intracellular organelles, thereby increasing the intracellular Ca2+ concentration which, in turn, modulates sundry cellular processes (see Calcium signalling). Structurally, it is a dinucleotide that only differs from the house-keeping enzyme cofactor, NADP by a hydroxyl group (replacing the nicotinamide amino group) and yet this minor modification converts it into the most potent Ca2+-mobilizing second messenger yet described. NAADP acts across phyla from plants to humans.

=== Confluent === Sometimes, the blisters merged into sheets, forming a confluent rash, which began to detach the outer layers of skin from the underlying flesh. Patients with confluent smallpox often remained ill even after scabs had formed over all the lesions. In one case series, the case-fatality rate in confluent smallpox was 62%.

=== Closure === McDonald's announced on May 23, 2025, that the CosMc's concept would cease operations at all five remaining locations (four in Texas and one in Illinois). The company indicated that starting one month later, the rewards program, mobile ordering and app would no longer function, and rolling closures of the physical locations would begin. Citing learnings from proofs of concepts at the pilot locations, they expect to test some of the most successful beverage concepts at several mainline McDonald's restaurants. CEO Chris Kempczinski stated that the concept was “quarantining the complexity in a stand-alone concept.” He also stated that brand contradiction, absence of experience, and a steep loss in revenue and sales were the reasons why the concept was shutting down.

Sources: en.wikipedia.org

Frequently asked questions